Close menu




August 14th, 2020 | 08:07 CEST

EXMceuticals, Nebelhornbahn, Syzygy - where entry opportunities now exist

  • Investments
Photo credits: pixabay.com

While the share prices of a variety of large companies have already returned to pre-Covid-19 price levels, the shares of small and mid-caps are often still trading at significantly lower levels. Here, there may be opportunities with price potential that can offer attractive returns for investors. It may therefore be worthwhile to take a closer look at some business models and companies.

time to read: 3 minutes | Author: Mario Hose
ISIN: DE0005104806 , CA30207T1049 , DE0008271107

Table of contents:


    With focus on cannabis

    EXMceuticals describes itself as a medical cannabis company that firmly believes in the potential health and wellness benefits of hemp and cannabis. The company is an emerging player in the market with high ambitions and the goal to become a major producer of high quality EU GMP cannabis and hemp ingredients. According to its own statements, the management is building an extraction and refining facility of the highest standards near Lisbon, Portugal, which will be dedicated to the production of cannabis material with API quality active pharmaceutical ingredients. The company is focused on providing the right ingredients for customers in the medical and wellness industry.

    EXMceuticals recently announced that loans totaling CAD 4,605,171 were converted into 23,025,855 new shares of the company. The conversion price was CAD 0.20 per share. All shares are subject to a four-month hold period expiring on November 25, 2020. According to the announcement, Jonathan Summers, CEO of the Company, also took advantage of the loan conversion offer and received 11,270,855 shares, representing approximately 16.4% of the company.

    Strengthening of market position and business model

    The Nebelhornbahn-AG was founded in 1927 and the company operates the cable car of the same name on the summit of the Nebelhorn in the Allgäu Alps. The Nebelhornbahn has been in operation since 1930 and has been renewed and renovated several times since then. The core business of the Nebelhornbahn-AG is the operation of the Nebelhorn mountain railway as well as the associated catering businesses in Oberstdorf. The Nebelhorn is a popular excursion destination and offers a wide range of hiking, touring and climbing opportunities in summer and a large, snow-covered ski area in winter. The region in the Allgäuer Alps stands out as the highest ski area in the Allgäu, with the mountain railway carrying more than 450,000 guests to the Nebelhorn every year.

    Since autumn 2019, the current renewal of the Nebenhornbahn is already underway and the first construction measures for the new main lift have been successfully completed. Following the decision in May 2020 to accelerate the implementation of this major project, construction activities were also intensified in the current financial year. Starting in the 2021/2022 financial year, the analysts at GBC Research expect regular business operations to resume during the summer and winter seasons. For this financial period, they forecast sales revenues of EUR 13.23 million and a net profit of EUR 0.58 million. Based on their forecasts for the current financial year and subsequent years, the experts have lowered the price target for Nebelhornbahn-AG from EUR 50.02 to EUR 45.60 per share.

    Sales and earnings forecast raised

    Founded in 1995, the SYZYGY Group is one of the leading consulting and implementation partners for the transformation in marketing and sales. SYZYGY creates, orchestrates and designs digital experiences and products for brands, companies and people. Strategy, products and activation are the central services of the group. Technology is the connecting and scaling element. The main focus of activities lies in strategic consulting, conception and design, technical realisation of brand platforms, business applications, websites, hosting, digital campaigns and mobile apps. Performance marketing and media services such as media planning, search engine marketing and optimisation also represent an important business area. Digital illustrations, virtual reality (VR) and augmented reality (AR) as well as animations complete the range of services.

    As expected, the effects of the Covid-19 pandemic have also left their mark on SYZYGY AG. In the first half of 2020, sales declined by -14.6 % to EUR 26.95 million (previous year: EUR 31.57 million). In the second quarter, which was particularly affected by the pandemic, the company even recorded a decline in sales of -24.1 %. However, the SYZYGY management has confirmed its forecasts for the current financial year 2020. For the second half of 2020, the business environment is expected to improve overall and the analysts of GBC Research have therefore slightly raised their previous forecasts for 2020. As part of their DCF valuation model, they have raised their previous price target from EUR 9.25 to EUR 9.40 and continue to assign a 'Buy' rating.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Mario Hose

    Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

    About the author



    Related comments:

    Commented by André Will-Laudien on January 31st, 2023 | 14:50 CET

    E-mobility 2023: The Tesla hunters are coming! BYD, Lucid Motors, Tocvan Ventures. Will the Varta share now also fly?

    • Mining
    • Gold
    • Electromobility
    • Investments

    It Is hard to believe! The Tesla share is once again making a name for itself. Analysts went into the presentation of the annual figures with cautious expectations because there were many negative rumors surrounding Elon Musk's electronics company: Fewer sales? Cars on stockpile? Again, it came as no one had expected it. Elon Musk delivered and simultaneously mocked all the shorties who wanted to push his stock below USD 100 at the turn of the year. This gambit went badly wrong because Tesla was able to deliver even better figures than expected, and there was no stopping the share. With plus 70% in only 4 weeks, the Tesla share belongs to the shooting stars since the turn of the year - the short sellers must have lost their desire completely. But the variety of interesting shares is significant. Where are the opportunities for e-investors lurking?

    Read

    Commented by Nico Popp on January 31st, 2023 | 14:33 CET

    This new project changes everything: Deutsche Bank, Aspermont, Alibaba

    • Digitization
    • Innovations
    • Technology
    • Investments

    When processes go digital, great opportunities arise: automation and scaling can ensure growth and turn established business models into high-flyers. But which companies should investors actively support in their transformation? Where is there real potential for investors, and where are companies just spreading buzzwords? We highlight three stocks for you.

    Read

    Commented by André Will-Laudien on January 30th, 2023 | 09:13 CET

    Mega biotech rally 2023! Defence Therapeutics, Bayer, BioNTech, Morphosys - Where to put the money?

    • Biotechnology
    • Cancer
    • Covid19
    • Investments

    Who would have thought it? Since the beginning of the year, the stock markets have been jubilant despite difficult predictions about the economic trend in 2023. High inflation and rising interest rates are not a good breeding ground for the popular biotech stocks because they have to constantly refinance their research expenses. As the risk fee is readjusted as costs rise, investors demand higher premiums for providing money. However, some biotech stocks have taken off since the beginning of the year despite adverse conditions. What is their secret?

    Read